Dicerna Pharmaceuticals (DRNA) PT Lowered to $22 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Reiterates Buy Rating on Dicerna Pharmaceuticals (DRNA)
March 12, 2019 6:48 AM EDTStifel analyst reiterated a Buy rating and $22.00 price target on Dicerna Pharmaceuticals (NASDAQ: DRNA)
For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.
Shares of Dicerna Pharmaceuticals closed at $11.74 yesterday.
... MoreDicerna Pharma (DRNA) Misses Q4 EPS by 7c, Revenues Miss
March 11, 2019 4:26 PM EDTDicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.54 million versus the consensus estimate of $7.78 million.
2018 was a year of tremendous achievement for Dicerna. During the year, we met each of our key strategic objectives, as we obtained strong proof-of-concept (POC) data for our lead... More
